Close Menu

This article has been updated with additional information from Centogene's earnings call.

NEW YORK – Centogene on Thursday morning reported a 52 percent year-over-year increase in Q4 revenues, driven by its pharmaceutical business, and a 21 percent increase in revenues for 2019.

"To date, we have been able to operate our business throughout this crisis without too much disruption," said Centogene CEO Arndt Rolfs during a conference call to discuss the financial results, commenting on the COVID-19 pandemic.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.